NCT05207761View on ClinicalTrials.gov

Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

October 18, 2022

Study Completion Date

November 2, 2022

Conditions
Glaucoma
Interventions
DRUG

D565

Q.D. in both eye

DRUG

D930

T.I.D in both eye

Trial Locations (1)

Unknown

Seoul National University College of Medicine and Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05207761 - Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930 | Biotech Hunter | Biotech Hunter